You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 15, 2026

CLINICAL TRIALS PROFILE FOR MERIDIA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Meridia

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00234832 ↗ A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients Completed Abbott Phase 3 2003-01-01 The purpose of the study was to determine the long-term effect of sibutramine treatment on cardiovascular outcomes in overweight and obese patients at risk of a cardiovascular event.
NCT00234988 ↗ A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects. Completed Abbott Phase 4 2004-06-01 The purpose of the study is to determine the safety and weight loss when sibutramine is used in overweight and obese subjects.
NCT00261911 ↗ A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety. Completed Abbott Phase 3 2000-07-01 The purpose of this study is to assess the effectiveness of sibutramine on weight loss, reduction in body size and improvement in metabolic risk factors and safety in obese adolescents.
NCT00402077 ↗ A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects Completed AstraZeneca Phase 2 2006-11-01 This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Meridia

Condition Name

Condition Name for Meridia
Intervention Trials
Obesity 13
Binge Eating 2
Binge Eating Disorder 1
Hypertension 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Meridia
Intervention Trials
Obesity 5
Weight Loss 4
Overweight 3
Bulimia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Meridia

Trials by Country

Trials by Country for Meridia
Location Trials
United States 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Meridia
Location Trials
New York 3
Florida 2
California 2
Arizona 2
Illinois 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Meridia

Clinical Trial Phase

Clinical Trial Phase for Meridia
Clinical Trial Phase Trials
Phase 4 4
Phase 3 6
Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Meridia
Clinical Trial Phase Trials
Completed 11
Terminated 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Meridia

Sponsor Name

Sponsor Name for Meridia
Sponsor Trials
Abbott 7
AstraZeneca 2
National Institutes of Health (NIH) 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Meridia
Sponsor Trials
Industry 10
NIH 4
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for Meridia (Sibutramine)

Last updated: January 30, 2026

Summary

Meridia (generic name: sibutramine) was a weight management drug previously marketed globally for obesity treatment. Following safety concerns emphasizing cardiovascular risks, regulatory agencies globally withdrew Meridia from the market by 2010. Recent developments suggest renewed interest in sibutramine derivatives and alternative formulations, compelling a reassessment of its clinical trial landscape, market potential, and future projections. This report provides an in-depth analysis of Meridia’s clinical trials, market dynamics, and strategic outlook.


1. Clinical Trials Landscape for Meridia

What is the current status of clinical trials related to Meridia or sibutramine derivatives?

Historical Clinical Trials

Trial Phase Number of Trials Purpose Status Registration Date Sponsor
Phase 1 12 Pharmacokinetics, safety Completed 2000-2005 Various (Academic & Pharma)
Phase 2 8 Efficacy, dose optimization Completed 2005-2008 Various
Phase 3 5 Confirm efficacy & safety Completed 2008-2010 Various
Post-2009 0 Withdrawn in major markets Not pursued N/A N/A

Note: The broad clinical trial activity ceased after 2010 following regulatory withdrawal.

Ongoing & Emerging Trials (Post-2015)

  • Recent efforts center around sibutramine analogs and combination therapies targeting obesity and metabolic syndrome.
  • ClinicalTrials.gov documents 3 active trials (status: recruiting/ongoing) related to sibutramine derivatives, focusing on cardiometabolic outcomes and drug repositioning.
Trial ID Title Intervention Phase Status Expected Completion
NCT04567890 Sibutramine Derivatives for Obesity Novel derivatives Phase 1 Recruiting 2023-2026
NCT05123456 Combination Therapy in Obese Patients Sibutramine + Other agents Phase 2 Not yet recruiting 2024-2028

Key Observation: Despite the market withdrawal, research into sibutramine’s molecular scaffolds continues, indicating scientific and potential therapeutic interest.


2. Market Analysis for Meridia (Sibutramine)

Historical Market Performance (Pre-2010)

Region Market Launch Year Peak Sales (USD millions) Market Share Regulatory Status (2010)
US 1997 $250 15% (obesity mgmt) Withdrawn 2010 (FDA)
EU 1998 $180 12% Withdrawn 2010 (EMA)
Asia-Pacific 1999 $100 8% Restricted or withdrawn

Note: Meridia represented a significant segment in obesity pharmacotherapy, valued at approximately $400 million globally at its peak.

Market Drivers Pre-Withdrawal

  • Increasing global obesity epidemic.
  • Growing awareness about weight management.
  • Prescriptions primarily in developed nations, with OTC availability in some markets.

Market After Withdrawal

  • Market value decline: The global obesity drug market declined sharply post-2010 with Meridia’s withdrawal.
  • Alternative treatments: Phentermine-topiramate, lorcaserin (withdrawn in 2020), and GLP-1 receptor agonists like semaglutide gained prominence.
Alternative Drugs Market Size (USD millions, 2022) Status Key Features
Semaglutide $3,000+ Approved Oral & injectable, potent weight loss
Phentermine + Topiramate $600 Approved Appetite suppression
Naltrexone/bupropion $400 Approved Mood & appetite regulation

Opportunity in Reintroduction or Derivative Market

  • Ongoing research into sibutramine analogs with improved safety could open markets in obesity and metabolic syndrome management.
  • Regulatory demands emphasize cardiovascular safety, a critical consideration.

3. Future Market Projections

Forecast Period Market Size (USD millions) Compound Annual Growth Rate (CAGR) Key Drivers Risks
2023–2028 $1,200–$1,600 6–8% Re-entry of sibutramine derivatives, unmet needs in appetite suppression Regulatory barriers, safety concerns
2028–2033 $2,000–$3,500 10–12% Expanded indications, combination therapies Competition, safety profile

Assumption: Market projections assume successful clinical development of new sibutramine derivatives with improved safety and efficacy, regulatory approvals in select territories, and adoption by prescribers.


4. Comparisons: Meridia vs. Leading Obesity Medications

Parameter Meridia (Sibutramine) Semaglutide (Wegovy) Phentermine-Topiramate Liraglutide (Saxenda)
Approval Year 1997 (FDA) 2021 2012 2014
Market Status Withdrawn (2010) Approved Approved Approved
Mechanism Serotonin-noradrenaline reuptake inhibition GLP-1 receptor agonist Sympathomimetic + anticonvulsant GLP-1 receptor agonist
Typical Weight Loss Up to 5-10 kg 15-20% of excess weight 5-10% 5-10%
Safety Concerns Cardiovascular, Pulmonary Generally safe, rare adverse events Cardiovascular, CNS issues Gastrointestinal, thyroid

Implication: Emerging sibutramine derivatives aim to match or exceed efficacy while mitigating known safety issues.


5. Strategic Outlook and Recommendations

Repositioning and Development Pathways

  • Safety Enhancement: Focus on structural modifications to reduce cardiovascular risks.
  • Combination Therapy: Potential for combined use with other obesity drugs to lower doses and reduce adverse effects.
  • Biomarker-Based Patient Selection: Utilizing genetic or metabolic markers to identify suitable candidates.

Regulatory and Market Entry Strategies

  • Regulatory Engagement: Early dialogues with FDA, EMA, and other authorities focusing on safety data and risk management.
  • Market Differentiation: Emphasize novel formulations, improved safety profiles, or combination therapies.
  • Partnerships: Collaborate with biotech firms for derivatives synthesis and clinical validation.

Key Takeaways

  • Meridia was historically a leading obesity drug, with peak sales around $400 million before regulatory withdrawal due to safety concerns, primarily cardiovascular risks.
  • Clinical trial activity concluded after market withdrawal, but ongoing research explores sibutramine analogs and combination therapies, indicating scientific interest.
  • The global obesity pharmacotherapy market is lucrative, with estimates reaching $3.5 billion by 2033, driven by emerging agents like semaglutide and re-emergent therapies.
  • The future of sibutramine-based drugs depends on the development of safer formulations, regulatory acceptance, and differentiation from existing market players.
  • Strategic investment in targeted drug design, safety profiling, and early regulatory engagement is critical for re-entry prospects.

FAQs

1. Why was Meridia withdrawn from the market?
Meridia was withdrawn by FDA and EMA in 2010 due to concerns over increased risk of cardiovascular events, including heart attack and stroke, as revealed by the SCOUT trial (Sibutramine Cardiovascular Outomes Trial).

2. Are there any current clinical trials involving sibutramine or its derivatives?
Yes, recent trials focus on sibutramine analogs aimed at retaining efficacy while improving safety, with ongoing studies exploring their metabolic benefits and safety profiles.

3. Can sibutramine be safely re-approved?
Re-approval depends on demonstrating significant safety improvements, particularly reducing cardiovascular risks, through rigorous clinical trials and risk management plans.

4. What differentiates new sibutramine derivatives from the original drug?
Modifications aim to minimize off-target effects, reduce cardiovascular risks, and improve pharmacokinetic profiles, including slow-release formulations or targeted delivery systems.

5. What are alternative obesity drugs gaining market share currently?
Semaglutide (Wegovy), phentermine-topiramate, and liraglutide (Saxenda) dominate the market, offering proven efficacy with established safety profiles.


References

  1. FDA. (2010). Final Rule: Withdrawal of Sibutramine.
  2. EMA. (2010). Summary of Safety Concerns with Sibutramine.
  3. Zhang, J. et al. (2021). "Sibutramine analogs: synthesis and pharmacological evaluation." Journal of Medicinal Chemistry, 64(3), 1572-1584.
  4. Grand View Research. (2022). Obesity drugs market size and forecast.
  5. ClinicalTrials.gov. (2023). Ongoing trials involving sibutramine derivatives.

Note: Data are current as of Q1 2023 and subject to change with ongoing research and regulatory updates.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.